title: Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient.
abstract: Blood lymphocytes of a HLA-A2 positive breast cancer patient were stimulated with either MCF-7 or MDA-MB-231, i.e., HLA-A2-matched allogeneic breast carcinoma cell lines. Several CD8+ CTL clones with reactivity against the stimulator cells but not against K562 were generated. Reactivity could be blocked with monoclonal antibody (mAb) W6/32, MA2.1, and/or BB7.2, indicating that the clones are HLA-class I and HLA-A2 restricted. The CTL clones generated following stimulation with MCF-7, recognized various other allogeneic HLA-A2+ tumor cell lines, including breast carcinoma, renal cell carcinoma, and melanoma cell lines, but not HLA-A2 tumor cell lines. The CTL clones did not recognize normal HLA-A2+ cells including breast epithelial cells, renal proximal tubular epithelial cells (PTEC), or EBV-transformed B cells including the autologous EBV cell line. In contrast to the CTL clones induced with MCF-7, the reactivity of the clones stimulated with MDA-MB-231, was limited to the stimulator cell MDA-MB-231. Cytotoxicity assays utilizing T2 cells loaded with peptides as target cells indicated that none of the examined CTL-epitopes derived from HER-2/neu, Muc-1, Ep-CAM-1, and p53 were recognized by the CTL clones generated. Our findings underscore that breast cancer is an immunogenic tumor and that HLA-class I-matched allogeneic tumor cells can be used as stimulator cells to generate tumor-specific CTL from peripheral blood of a breast cancer patient with specificity for an antigenic determinant that is broadly expressed on tumor cells from various origins or with specificity limited to the breast cancer stimulator cell.
authors.affiliation: Department of Clinical Oncology, Leiden University Medical Centre, The Netherlands. Verdegaal@mail.medfac.LeidenUniv.nl
authors.forename: E M
authors.initials: EM
authors.lastname: Verdegaal
authors.forename: D B
authors.initials: DB
authors.lastname: Huinink
authors.forename: C
authors.initials: C
authors.lastname: Hoogstraten
authors.forename: A K
authors.initials: AK
authors.lastname: Marijnissen
authors.forename: M B
authors.initials: MB
authors.lastname: Gorsira
authors.forename: F H
authors.initials: FH
authors.lastname: Claas
authors.forename: S
authors.initials: S
authors.lastname: Osanto
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D001943:Breast Neoplasms / Q000097:blood / Q000276:immunology*; D018968:CD58 Antigens / Q000096:biosynthesis; D002461:Cell Line, Transformed; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D005260:Female; D015789:HLA-A2 Antigen / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis; D020014:K562 Cells; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D000951:Antigens, Neoplasm; D018968:CD58 Antigens; D018984:Epitopes, T-Lymphocyte; D015789:HLA-A2 Antigen; D010455:Peptides; D018799:Intercellular Adhesion Molecule-1